About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics is a clinical-stage biotechnology company focused on the development of best-in-class autologous cellular therapeutics for the treatment of highly debilitating neurodegenerative diseases.
Our technology platform
We hold rights to clinical development and commercialization of the NurOwn® technology platform through an exclusive, worldwide licensing agreement.
Elsewhere on this site
- 01
Leadership
The executive team, the board of directors and the scientific advisory board.Read more - 02
Science
The autologous cellular therapy platform, MSC-NTF cells, cell production and the intellectual property behind them.Read more - 03
Pipeline
Clinical programs in ALS and progressive MS, and preclinical work in other neurodegenerative diseases.Read more - 04
Careers
What the work is like, and any positions currently open across cell production, clinical operations, regulatory and R&D.Read more - 05
Contact
Patient and caregiver, investor, media and partnering inquiries, and the corporate headquarters.Read more
BrainStorm's autologous MSC-NTF cell therapy (NurOwn®, debamestrocel) is investigational and has not been approved by the FDA or any other regulatory authority.